Dr. Wassim Kassouf, Urologist, Montreal, QC

Dr. Wassim Kassouf, urologist, Montreal  Wassim Kassouf Academic title(s): Professor, Department of Surgery (Division of Urology) Wassim Kassouf Contact Information Phone: (514) 934-8246 Current research: Biology and Therapy for Bladder Cancer Molecular Markers for Bladder Cancer Patterns of practice and outcomes in urologic oncology Clinical Interests: Urologic Oncology (bladder, prostate, kidney, testes, and penile cancer) Robotic, laparoscopic, and open surgery Biography: Dr. Wassim Kassouf, urologist, Montreal   completed a clinical and research fellowship in urologic oncology at M. D. Anderson Cancer Center in Houston, Texas following medical school and urology residency at McGill University. He then arrived back on faculty at the McGill University Health Center in 2006. Dr. Wassim Kassouf, urologist, Montreal clinical practice focuses on all aspects of urologic oncology (including bladder, prostate, renal, and testes cancer) whereas his research focuses on bladder cancer. Presently, he is the Program Director of the McGill Urology Residency. He also serves as the chair of the MUHC Urology Quality of Care Assurance committee and a member of the Royal College Urology Specialty committee as well as the Royal College Examination board committee. He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 230 peer-review manuscripts and book chapters. He has obtained independent peer-reviewed grant funding from the CRS and CIHR. He is an associate editor for BMC Urology and is on the editorial board of Urology, CUAJ, Clinical Cancer Investigation Journal, and International Brazilian Journal of Urology. He is a course director on bladder and upper tract cancers at the SIU and AUA. He is the founder of the national Canadian Bladder Cancer Network, a cofounder of Bladder Cancer Canada, chair of the National Cancer Institute of Canada’s disease-oriented group in bladder cancer, Vice-President (communications) of the Canadian Urological Association, and an executive member of the NIH Genitourinary steering committee Bladder Cancer Task Force. Dr Kassouf is a graduate of the AUA Leadership Program and received several awards including the American Urological Association Research Scholar Award, Canadian Urological Association Scholarship Award, FRSQ Clinician Scientist Research Scholar Award, and the Everett C. Reid Teaching Excellence Award. Selected publications:

Dr. Wassim Kassouf, urologist, Montreal Is in good standing with the College of Physicians and Surgeons of Canada, Dr. Wassim Kassouf, urologist, Montreal is in good standing with the Canadian Urological Society and the Canadian Medical Association

Keywords: Benign Prostatic Hypertrophy, Benign prostatic hyperplasia (BPH) , Colon Cancer Screening & Treatment , Prostate Cancer, Hypothyroidism, Laparoscopic Surgery, Obesity Prostate Cancer treatment 

Dr. Wassim Kassouf, urologist, Montreal 

Video by Dr Miles Mannas : BPH treatment and surgical options

( Dr. Wassim Kassouf, Urologist, Montreal, QC) is in good standing with the College of Physicians and Surgeons.

If you are looking for local services or  treatment froma local urologist   in the office or hospital from a Urologist, contact a provider such as ( Dr. Wassim Kassouf ) to inquire if they are accepting patients or you need a referral.   Phone number to book an appointment Phone: (514) 934-8246  ( Dr. Wassim Kassouf ) Is in good standing with the College of Physicians and Surgeons ( Dr. Wassim Kassouf ) Is in good standing with the Canadian Urological Society ( Dr. Wassim Kassouf ) Is in good standing with the Canadian Medical Association

Keywords: Cancer: BPH, Cancer: Prostate Nutrition, Cancer: Breast Cancer, Cancer: Colon and Rectal Cancer Cancer: Lung Cancer, Cancer: Melanoma, Cancer: Ovarian Cancer, Cancer: Prostate Cancer

The speaker in the video may have no association with ( Dr. Wassim Kassouf, Urologist Montreal, QC ). 
( Dr. Wassim Kassouf, Urologist Montreal, QC ), may talk about some of the conditions and some of the treatment options shown on the videos. Always talk with your Local Urologist  about the information you learnt from the videos in regards to Male incontinence Contino® treatments and procedures the Local Urologist  could  perform and if they would be appropriate for you. Remember good information from your Local Urologist  is the corner stone to understanding your condition or disease.

Health Talks:

Sexual preservation for BPH prostate surgery

Urology Practice isa great pleace to start to look into If you’re experiencing symptoms of male incontinence, a local urologist can help. A local urologist can ask about your symptoms and recommend further testing or male incontinence treatment. Urethral inserts like Contino® are temporarily inserted into the urethra (the tube which carries urine to the outside of the body) to prevent or reduce bladder leakage. Damage to the kidneys can lead to swelling in the hands and ankles, high blood pressure, and other symptoms. 

Please contact ( Dr. Wassim Kassouf, Urologist Montreal, QC ) to enquire if this health care provider is accepting new patients. Prostate Cancer NOW is part of the Now Health Network and its focus is on muscular and skeletal  conditions.  In summary, there are many different treatments for prostate cancer.  Identifying the best treatment will depend on your specific situation and your preference after discussion with your doctor. It is not true Asian men have the lowest risk of developing prostate cancer. African men have the highest risk. Often seeing a local urologist in Toronto can help. 

Medications like alpha blockers don't actually treat BPH, they treat the symptoms by relaxing the muscle around the urethra, so thereby reducing some of the resistance.

Sometimes we will add in a second line medication in order to try and shrink the prostate. These medications are called the five alpha reductase inhibitors. So we have Proscar or Avodart These are medications which work by lowering the conversion of testosterone within the prostate. Over a period of 6 to 12 months, this can shrink the prostate by around 20%.